EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting

A Zilioli, A Rosenberg, R Mohanty, A Matton, T Granberg, G Hagman, J Lötjönen, M Kivipelto, E Westman

Journal of Neurology · 2025

DOI: 10.1007/s00415-024-12853-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, 2025. Verfasst von A Zilioli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University-Hospital of Parma, Parma, Italy. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Amyloid beta-Peptides, Atrophy, Alzheimer Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predicting amyloid status is crucial in light of upcoming disease-modifying therapies and the need to identify treatment-eligible patients with Alzheimer’s disease. In our study, we aimed to predict CSF-amyloid status and eligibility for anti-amyloid treatment in a memory clinic by (I) comparing the performance of visual/automated rating scales and MRI volumetric analysis and (II) combining MRI volumetric data with neuropsychological tests and APOE4 status. Two hundred ninety patients underwent a comprehensive assessment. The cNeuro cMRI software (Combinostics Oy) provided automated computed rating scales and volumetric analysis. Amyloid status was determined using data-driven CSF biomarker cutoffs (Aβ42/Aβ40 ratio), and eligibility for anti-Aβ treatment was assessed according to recent recommendations published after the FDA approval of the anti-Aβ drug aducanumab. The automated rating scales and volumetric analysis demonstrated higher performance compared to visual assessment in predicting Aβ status, especially for parietal-GCA (AUC = 0.70), MTA (AUC = 0.66) scores, hippocampal (AUC = 0.68), and angular gyrus (AUC = 0.69) volumes, despite low global accuracy. When we combined hippocampal and angular gyrus volumes with RAVLT immediate recall and APOE4 status, we achieved the highest accuracy (AUC = 0.82), which remained high even in predicting anti-Aβ treatment eligibility (AUC = 0.81). Our study suggests that automated analysis of atrophy rating scales and brain volumetry outperforms operator-dependent visual rating scales. When combined with neuropsychological and genetic information, this computerized approach may play a crucial role not only in a research context but also in a real-world memory clinic. This integration results in a high level of accuracy for predicting amyloid-CSF status and anti-Aβ treatment eligibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingAmyloid beta-PeptidesAtrophyAlzheimer DiseaseBrainHumansMaleFemaleAgedMiddle AgedAntibodies, Monoclonal, HumanizedNeuropsychological TestsAged, 80 and overApolipoprotein E4Peptide FragmentsBiomarkers

Stichwörter der Autor:innen

Anti-amyloid treatment eligibilityAtrophy rating scalesBrain volumetryNeuroimaging

Substanzen

Amyloid beta-PeptidesAntibodies, Monoclonal, HumanizedaducanumabApolipoprotein E4Peptide Fragmentsamyloid beta-protein (1-42)Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, University-Hospital of Parma, Parma, Italy.
  • Population Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
  • Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Förderung

  • Karolinska Institute

Zitieren

APA

Zilioli, A., Rosenberg, A., Mohanty, R., Matton, A., Granberg, T., Hagman, G., Lötjönen, J., Kivipelto, M., & Westman, E. (2025). Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting. Journal of Neurology. https://doi.org/10.1007/s00415-024-12853-9

Vancouver

Zilioli A, Rosenberg A, Mohanty R, Matton A, Granberg T, Hagman G, et al. Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting. Journal of Neurology. 2025. doi:10.1007/s00415-024-12853-9

BibTeX
@article{Zilioli2025,
  author = {Zilioli, A and Rosenberg, A and Mohanty, R and Matton, A and Granberg, T and Hagman, G and Lötjönen, J and Kivipelto, M and Westman, E},
  title = {Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting},
  journal = {Journal of Neurology},
  year = {2025},
  doi = {10.1007/s00415-024-12853-9}
}
Kostenlos starten →